Lantheus Holdings, Inc. (LNTH): Price and Financial Metrics
LNTH Price/Volume Stats
| Current price | $63.81 | 52-week high | $100.85 |
| Prev. close | $62.33 | 52-week low | $50.20 |
| Day low | $61.47 | Volume | 798,458 |
| Day high | $64.01 | Avg. volume | 1,059,034 |
| 50-day MA | $60.65 | Dividend yield | N/A |
| 200-day MA | $66.05 | Market Cap | 4.37B |
LNTH Stock Price Chart Interactive Chart >
Lantheus Holdings, Inc. (LNTH) Company Bio
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company was founded in 1956 and is based in North Billerica, Massachusetts.
Latest LNTH News From Around the Web
Below are the latest news stories about LANTHEUS HOLDINGS INC that investors may wish to consider to help them evaluate LNTH as an investment opportunity.
New Year, New Gains: The 3 Best AI Stocks to Buy in 2024These AI stocks offer substantial upside potential compared to the overextended chip players that dominated the theme in 2023. |
13 Most Promising Future Stocks To Buy According To Hedge FundsIn this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. Investing, for the most part, is all […] |
Lantheus Holdings Is Charting a Path to Sustainable Growth and ValueEvaluating a leader in the global precision diagnostics market |
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate CancerPhase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific m |
Lantheus Holdings (LNTH) Crossed Above the 200-Day Moving Average: What That Means for InvestorsShould investors be excited or worried when a stock crosses above the 200-day simple moving average? |
LNTH Price Returns
| 1-mo | 7.82% |
| 3-mo | 20.21% |
| 6-mo | -8.33% |
| 1-year | -28.79% |
| 3-year | 202.13% |
| 5-year | 164.22% |
| YTD | 2.92% |
| 2023 | 21.66% |
| 2022 | 76.39% |
| 2021 | 114.16% |
| 2020 | -34.23% |
| 2019 | 31.05% |
Continue Researching LNTH
Here are a few links from around the web to help you further your research on Lantheus Holdings Inc's stock as an investment opportunity:Lantheus Holdings Inc (LNTH) Stock Price | Nasdaq
Lantheus Holdings Inc (LNTH) Stock Quote, History and News - Yahoo Finance
Lantheus Holdings Inc (LNTH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...